The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics

American Journal of Nephrology

Volumn 46, Issue 6, 2018, Pages 462-472

  Jardine, Meg J ^a,b   Mahaffey, Kenneth W ^c   Neal, Bruce ^a,b,d,e   Agarwal, Rajiv ^f   Bakris, George L ^g   Brenner, Barry M ^h   Bull, Scott ⁱ   Cannon, Christopher P ^h   Charytan, David M ^h   De Zeeuw, Dick ^j   Edwards, Robert ⁱ   Greene, Tom ^k   Heerspink, Hiddo J L ^j   Levin, Adeera ^l   Pollock, Carol ^m   Wheeler, David C ⁿ   Xie, John ⁱ   Zhang, Hong ^o   Zinman, Bernard ^p   Desai, Mehul ⁱ   Perkovic, Vlado ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^o PEKING UNIVERSITY FIRST HOSPITAL   (China)

^p MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

Canagliflozin; Chronic kidney disease; Diabetic nephropathy; Renal outcomes

Indexed keywords

CANAGLIFLOZIN; EMPAGLIFLOZIN;

ADULT; ALBUMINURIA; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; MALE; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; URINALYSIS;

EID: 85038113623     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000484633     Document Type: Article

References (27)

1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J, Rodgers A, Gallagher M, Kotwal S, Cass A, Perkovic V: Worldwide access to treatment for end-stage kidney disease: A systematic review. Lancet 2015; 385: 1975- 1982.
2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545-1602.
3. International Diabetes Federation: IDF Diabetes Atlas, ed 7. Brussels, International Diabetes Federation, 2015.
4. Astor BC, et al: Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79: 1331-1340.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
7. Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K: Canagliflozin: A sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015; 1358: 28-43.
8. Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G: Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: A pooled analysis. Curr Med Res Opin 2017; 33: 553-562.
9. Erondu N, Desai M, Ways K, Meininger G: Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38: 1680-1686.
10. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G: Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016; 101: 157-166.
11. US Food and Drug Administration: FDA Drug Safety Communication: Interim Clinical Trial Results Find Increased Risk of Leg and Foot Amputations, Mostly Affecting the Toes, with the Diabetes Medicine Canagliflozin (Invokana, Invokamet); FDA to In-vestigate. http://www.fda.gov/Drugs/DrugSafety/ucm557507.htm (accessed November 9, 2017).
12. Desai M, Yavin Y, Balis D, Sun D, Xie J, Canovatchel W, Rosenthal N: Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2017; 19: 897-900.
13. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V: Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28: 368-375.
14. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.
15. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334.
16. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews D; CANVAS Program Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657.
17. Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D: Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes Endocrinol 2016; 4: 309-317.
18. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon S, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S: Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83: 517-523.
19. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V: Effects of intensive blood pressure lowering on the progression of chronic kidney disease: A systematic review and meta-analysis. CMAJ 2013; 185: 949-957.
20. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-597.
21. Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM: Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 1987; 80: 670-674.
22. Ballermann BJ, Brenner BM: Atrial natriuretic peptide and the kidney. Am J Kidney Dis 1987; 10: 7-12.
23. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D: Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis 2014; 63: 244-250.
24. Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS: GFR decline as an alternative end point to kidney failure in clinical trials: A meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis 2014; 64: 848-859.
25. Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR: Optimizing the analysis strategy for the CANVAS program-a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017; 19: 926-935.
26. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2011; 80: 572-586.
27. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schottker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Arnlov J; CKD Prognosis Consortium: Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3: 514-525.